Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04518462 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries
A Phase 3 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 121
- Enrollment target
NCT04518462 is a Phase 3 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 121 participants.
The verdict
NCT04518462, a Phase 3 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, randomized, double blinded, active controlled study in approximately 120 subjects undergoing lower extremity surgeries.
Interventions
- DRUG Exparel
- DRUG Bupivacaine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2021-04-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04518462
The ClinicalTrials.gov registry entry for NCT04518462 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT04518462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04518462 about?
NCT04518462 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries". This is a Phase 3, multicenter, randomized, double blinded, active controlled study in approximately 120 subjects undergoing lower extremity surgeries.
What is the current status of trial NCT04518462?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 121 participants. The study started on 2020-10-20. Estimated completion is 2021-04-05.
What interventions are being tested in trial NCT04518462?
The interventions under investigation include: Exparel (DRUG), Bupivacaine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT04518462?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.